Dronedarone: A review of characteristics and clinical data

Critical Pathways in Cardiology

Volumn 9, Issue 2, 2010, Pages 94-101

  Baroletti, Steven ^a   Catella, Jennifer ^b   Ehle, Michael ^b   Cheng, Judy W M ^c  

^a METROWEST MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Arrhythmias; Dronedarone cardiology

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; CYCLOSPORIN; DIGOXIN; DRONEDARONE; GLYCOPROTEIN P INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MULTAQ; NEFAZODONE; PLACEBO; RITONAVIR; TELITHROMYCIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VORICONAZOLE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GRAPEFRUIT JUICE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINUS RHYTHM; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; DRUG INTERACTION;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DRUG INTERACTIONS; HUMANS;

EID: 77953563713     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0b013e3181dda1e6     Document Type: Review

References (25)

1. American Heart Association. 2009 Heart Disease and Stroke Statistics (online). Available at: http://circ.ahajournals.org/cgi/content/full/115/5/e69. Accessed January, 2010.
2. Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol. 1999;89:131R-138R.
3. Fuster V, Ryden LE, Cannom DS, et al. 2006 ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation. 2006;114:e257-e354. Available at: http://circ.ahajournals.org/cgi/content/ full/114/7/e257. Accessed January 2010.
4. Wyse Dg, Waldo AL, DiMarco JP, et al; The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillations. N Engl J Med. 2002;347:1825-1833.
5. Reiffel JA. A contemporary look at classic trials in atrial fibrillation: what do they really show and how might they apply to future therapies? Am J Cardiol. 2008;102:3H-11H.
6. Nichol G, McAlister F, Pham B, et al. Meta-analysis of randomized controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart. 2002;87:535-543.
7. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-1872.
8. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913-920.
9. Singh SN, Tang CX, Singh BN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation. J Am Coll Cardiol. 2006;48:721-730.
10. The AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42:20-29.
11. Deedwania PC, Singh BN, Ellenbogan K, et al. Spontaneous conversion an maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT).The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998;98:2574-2579.
12. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med. 1995;333:77-82.
13. Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol. 2008;127:299-306.
14. Zareba KM. Dronedarone: a new antiarrhythmic agent. Drugs Today (Barc). 2006;42:75-86.
15. Guiraudou P, Pucheu SC, Gayraud R, et al. Involvement of nitric oxide in amiodarone and dronedarone-induced coronary vasodilatation in guinea pig heart. Eur J Pharmacol. 2004;496:119-127.
16. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol. 2003;91:15D-26D.
17. Damy T, Pousset F, Caplain H, et al. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004;18: 113-123.
18. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007;64:785-791.
19. Product information. Multaq (dronedarone), Bridgewater, NJ, Sanofi-aventis 2009.
20. Davy JM, Herold M, Hoglund C, et al; ERATO Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of Dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156:527.e1-527.e9.
21. Touboul P, Brugada J, Capucci A, et al; DAFNE Investigators. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481-1487.
22. Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.
23. Kober L, Torp-Pedersen C, McMurray JJ, et al; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687.
24. Hohnloser SH, Crijns HJ, van Eickels M, et al; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2008;360:668-678.
25. Barquet P. DIONYSOS study results showed the respective profiles of dronedarone and amiodarone. Press release. Available at: http://en. sanofiaventis. com/binaries/20081223-dionysos-fe-en-en-tcm28-23624.pdf. Accessed December 2009.